iSOFT joins with Eclipsys for product development:
This article was originally published in Clinica
UK company iSOFT Group is to form a strategic partnership with US company Eclipsys to develop clinical solutions based around the Sunrise clinical management system. The deal allows iSOFT to distribute the Eclipsys Sunrise system in various European and Asian territories. iSOFT will take over the Eclipsys subsidiaries in Australia and the UK, the company says.
You may also be interested in...
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.
Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.
Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.